FUSED RING HETEROARYL COMPOUNDS AND THEIR USE AS TRK INHIBITORS

The disclosure provides novel chemical compounds represented by Formula (I) or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative...

Full description

Saved in:
Bibliographic Details
Main Authors KIM, MOONSOO, CHOI, SOONGYU, JUNG, MYUNG, EUN, LEE, KI, NAM, KIM, HYE, KYOUNG, LEE, CHAEWOON, JEONG, HANKYUL, CHOI, HYANG, YOON, CHEOLHWAN, LEE, GILNAM, KIM, JAY, HAK, KIM, HYUN, JUNG, SEO, JEONGBEOB, LEE, MINWOO, LEE, JAE, IL, KIM, MISOON
Format Patent
LanguageEnglish
French
Published 04.08.2016
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The disclosure provides novel chemical compounds represented by Formula (I) or a pharmaceutically acceptable salt, solvate, polymorph, ester, tautomer or prodrug thereof. The compounds can be used as an inhibitor of Trk and are useful in the treatment of pain, cancer, inflammation, neurodegenerative disease and certain infectious diseases. In some compounds of Formula I, Q is -CH=CR3C(O)Nr4R5, -C=CC(O)NR4R5,-C≡ CC(0)NR4R5, or (II). Cette invention concerne de nouveaux composés chimiques représentés par la Formule I ou un sel pharmaceutiquement acceptable, un solvate, un polymorphe, un ester, un tautomère ou un promédicament de celui-ci. Les composés peuvent être utilisés à titre d'inhibiteurs de Trk et sont utiles dans le traitement de la douleur, du cancer, de l'inflammation, des maladies neurodégénératives et certaines maladies infectieuses. Dans certains composés de Formule I, Q est -CH=CR3C(O)Nr4R5, -C=CC(O)NR4R5,-C≡ CC(O)NR4R5, ou (II).
Bibliography:Application Number: WO2015IB02521